The review stratifies mechanistic and clinical evidence across five major domains: malignant tumors, cardiovascular diseases, pulmonary disorders, orthopedic conditions, and metabolic diseases, while evaluating the development and risks of CTSK inhibitors.<h4>Results</h4>CTSK acts as a versatile protease in ECM remodeling. This evidence concerns the gene CTSK and lung disorder.